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Abstract 
 
Medulloblastoma is the most common malignant brain tumour in children and is associated with a poor 
outcome. We were interested in gaining further insight into the potential of targeting the human kinome 
as a novel approach to sensitize medulloblastoma to chemotherapeutic agents. A library of small 
interfering RNA (siRNA) was used to down-regulate the known human protein and lipid kinases in 
medulloblastoma cell lines. The analysis of cell proliferation, in the presence or absence of a low dose 
of cisplatin after siRNA transfection, identified new protein and lipid kinases involved in 
medulloblastoma chemoresistance. PLK1 (polo-like kinase 1) was identified as a kinase involved in 
proliferation in medulloblastoma cell lines. Moreover, a set of 6 genes comprising ATR, LYK5, MPP2, 
PIK3CG, PIK4CA and WNK4 were identified as contributing to both cell proliferation and resistance to 
cisplatin treatment in medulloblastoma cells. An analysis of the expression of the 6 target genes in 
primary medulloblastoma tumor samples and cell lines revealed over-expression of LYK5 and 
PIK3CG. The results of the siRNA screen were validated by target inhibition with specific 
pharmacological inhibitors. A pharmacological inhibitor of p110γ (encoded by PIK3CG) impaired cell 
proliferation in medulloblastoma cell lines and sensitized the cells to cisplatin treatment. Together, our 
data show that the p110γ phosphoinositide 3-kinase isoform is a novel target for combinatorial 
therapies in medulloblastoma. 
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Introduction 
 
Medulloblastoma is the most common malignant brain tumour in children and accounts for 
approximately 20% to 25% of all pediatric central nervous system tumours (1). There are hundreds of 
new cases worldwide each year, most of which occur at between 5 and 10 years of age (1, 2). 
Treatment of medulloblastoma involves surgery followed by chemotherapy and, in the case of children 
older than 3-5 years, radiotherapy (3, 4). Although these therapeutic approaches are often effective at 
shrinking the primary tumour, recurrence and metastasis frequently occur, so that the 5-year survival 
rate is below 50% for high-risk patients. Novel therapies are thus urgently required and will arise from 
a better understanding of the disease biology.  
Several reports have documented the involvement of protein and lipid kinases in 
medulloblastoma biology. Receptor tyrosine kinases (RTKs) such as ErbB-2, ErbB-4, insulin-like 
growth factor-I receptor (IGF-IR) and platelet-derived growth factor receptor (PDGFR) have been 
shown to be expressed and to control cell proliferation, survival and the development of metastasis in 
human medulloblastoma cells (1, 5). New therapies for medulloblastoma are emerging, which are 
based on blocking signalling by these RTKs to some of their downstream signalling targets such as 
phosphoinositide 3-kinase (PI3K), protein kinase B (PKB)/Akt, the mammalian target of rapamycin 
(mTOR) and mitogen-activated extracellular signal-regulated kinase activating kinase (MEK) (6-12). 
The ability to use RNA interference (RNAi) as a tool for gene silencing in mammalian cells has 
opened up the possibility of carrying out high-throughput loss-of-function screens in tissue culture 
systems (13-16). To identify new molecular targets for medulloblastoma, we have performed survival 
RNA interference (RNAi) screens targeting most of the known human protein and lipid kinases (719 
genes) using libraries of either short hairpin RNA (shRNA) in retroviral constructs, or small interfering 
RNA (siRNA). The analysis of cell proliferation after RNAi transfection in combination with cisplatin 
treatment identified new protein and lipid kinases involved in medulloblatoma cell responses. In 
particular, p110γ and LYK5, two kinases which had not previously been implicated in medulloblastoma 
biology, were shown to play a role in cell proliferation and chemoresistance by contributing to 
activation of the mTOR pathway.  
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Materials and methods 
 
siRNA library and screen set up 
DAOY medulloblastoma cells were transfected with a 96 well plate arrayed siRNA kinome library 
(Ambion) containing 2157 unique small interfering RNAs (siRNAs) targeting each of the 719 human 
kinase genes (3 individual siRNAs per gene). DAOY cells (4500 cells in 100 μl medium/well) were 
plated in DMEM (Dulbecco’s modified Eagle’s medium; Invitrogen) containing 10% FCS and 1% L-
glutamine and allowed to attach. siRNA transfections (5 pmol siRNA/well) were performed using 
Lipofectamine 2000 (Invitrogen) as per manufacture’s instructions for adherent cell lines, in two 
identical replica plates. At 24h after transfection, one replica plate was treated with 0.5 μM cisplatin 
(Bristol-Myers Squibb) and one replica plate with vehicle in media. Cell viability was assessed after 
further 48h by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] assay using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (Promega). 
On each plate, siRNA for GAPDH (Ambion), siCONTROL Non-Targeting siRNA Pool (Dharmacon) 
and siCONTROL RISC-Free siRNA (Dharmacon) were used as negative controls (one well each) and 
siCONTROL TOX was used as positive control for transfection efficiency. The screen was performed 
in triplicate and, for each individual siRNA, the mean values of the three independent experiments 
were calculated. The effect of each siRNA on cell proliferation was assessed dividing the mean of the 
3 replica wells by the mean of the 3 negative controls of the corresponding plate, and expressed as a 
percentage. For determination of the sensitivity to cisplatin treatment, surviving fractions were 
calculated as follows: Surviving fraction = log2mean (three replica cisplatin-treated wells) - log2mean 
(three replica vehicle-treated wells). In order to allow comparisons, the surviving fraction from all 27 
RNAi plates were combined and expressed as a median-centred Z score. Z-score normalization of the 
data within each well location of the plate was performed, subtracting the median surviving fraction 
from the surviving fraction of the individual siRNA and then dividing the difference by the standard 
deviation. The correction factor 1.4826 for large population size was used. To define effects on 
cisplatin resistance, a threshold of Z ≤ -2 for sensitization was used. 
 
Screen validation, shRNAs and plasmid transfections 
Two distinct siRNA species and one shRNA were used to revalidate hits from the screen. The siRNA 
sequences used for validation were the same as the ones used in the screen. Ambion Catalog 
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numbers of the siRNA sequences were used: PIK3CG#1 – ID: 143808, PIK3CG#2 – ID: 143807, 
PLK#1 – ID: 103548, PLK#2 – ID: 1341, LYK5#1 – ID: 43040, LYK5#2 – ID: 43116, ATR#1 – ID: 
103302, ATR#2 – ID: 82, PI4KA#1– ID: 1604, PI4KA#2 – ID: 144408, WNK4#1 – ID: 1105, WNK4#2 – 
ID: 1106. RNAi-mediated gene silencing was evaluated 48h after transfection. mRNA and protein were 
extracted in order to assess protein expression by Western blotting and mRNA expression by 
quantitative PCR. The shRNA-encoding plasmids used are part of the Human Kinase shRNA Release 
1.A2 library (Open Biosystems). The following plasmids were used: v2HS_36776 (MPP2), 
v2HS_179927 (LYK5) and v2HS_170020 (PIK3CG). The negative control vector (pSM2) containing a 
non-targeting shRNA sequence was used as shRNA control. To transfect DAOY medulloblastoma 
cells with plasmids, the Lipofectamine Plus reagent (Invitrogen) was used according to the 
manufacturer’s recommended protocol. 
 
Clinical samples 
Ethical approval to use residual tissue was obtained for all primary medulloblastoma samples used in 
this study. The samples used in this study and methods for RNA extraction have been previously 
described (17). Forty-seven medulloblastoma samples collected at diagnosis in a single institution 
between 1992 and 2004 (Dr. Lellouch-Tubiana, Necker Hospital, Paris) according to the French law of 
bioethics (Loi Huriet) were used for gene expression analyses. An independent set of 10 RNA-later-
preserved tumor tissues from the Swiss Pediatric Oncology Group Tumor Bank was obtained for 
mRNA and protein expression analysis.  
 
Expression profiling 
Gene expression profiles were obtained on the Affymetrix HG-U133 Plus 2.0 array, containing over 
54000 probe sets for transcripts and variants (17). The GCRMA procedure was used for normalization 
of gene expression data, which were subsequently converted into log2-values. Probes of interest have 
been considered for analysis and compared to expression levels of 9 normal cerebellum samples 
(GSM80616, GSM80617, GSM80618, GSM80619, GSM80626, GSM80636, GSM80637, GSM80638, 
and GSM80639; expression data are available on the public database Gene Expression Omnibus: 
http://www.ncbi.nlm.nih.gov/geo/). 
 
TaqMan real time quantitative RT-PCR  
on March 14, 2014. © 2011 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 7, 2011; DOI: 10.1158/1541-7786.MCR-10-0200 
 6
Total RNA from each tumour sample was converted into cDNA using the SuperScriptTM First-Strand 
Synthesis System (Invitrogen) for PCR according to manufacturer’s instructions. Assays-on-Demand 
Gene Expression products (Applied Biosystems) were used to measure mRNA expression levels of 
PLK1 (Hs00153444_m1), LYK5 (Hs00405851_m1), MPP2 (Hs00178428_m1), PIK3CG 
(Hs00176916_m1), PI4KA (Hs01021084_m1), WNK4 (Hs00260769_m1), ATR (Hs00354807_m1) and 
GAPDH (Hs99999905_m1; internal control gene). Normal human cerebellum was used as a reference 
(BioCat GmBh). Relative mRNA expression levels were calculated using the comparative threshold 
cycle (CT) method (18). 
 
Cell culture and treatments 
The cell lines’ provenience has been previously described (19). DAOY, UW-228 and PFSK human cell 
lines were purchased from the American Type Culture Collection. D341 and D425 MB cells were the 
kind gift of Dr. Henry Friedman (Duke University, Durham, NC). Cell lines that were not purchased 
from the American Type Culture Collection in 2009 were tested for their authentication by karyotypic 
analysis using molecular cytogenetic techniques, such as comparative genomic hybridization. DAOY 
medulloblastoma cell line was grown in Richter’s MEM Zinc option medium (Invitrogen) with 10% FCS 
(fetal bovine serum; Sigma) and penicillin/streptomycin (Invitrogen). PFSK primitive neuroectodermal 
tumor (PNET) cell line was grown in RPMI 1640 (Invitrogen) with 10% FCS and 
penicillin/streptomycin/L-glutamine. The UW-228 medulloblastoma cell line was grown in DMEM 
(Dulbecco’s modified Eagle’s medium; Invitrogen) with 10% FCS and penicillin/streptomycin/L-
glutamine. All cells were grown in a humidified atmosphere at 37° and 5% CO2. The inhibitors BI2536 
(Axon Medchem) and AS 252424 were dissolved in DMSO at 10 mM and diluted into cell culture 
medium just prior to use. 
 
Western Blotting 
Protein expression was analyzed by immunoblotting as previously described (11, 20) using antibodies 
specific for PI3K p110γ, LYK5 (STRAD N-13), LKB1, MPP2 (Santa Cruz Biotechnology), AMPKα, 
phospho-Akt (Ser473; Thr308), ATR, phospho-S6 (Ser 235/236 and Ser 240/244), phospho-4E-BP1 
(Cell Signaling Technology) and β-Actin (Sigma). The blots were quantified by densitometry using the 
software TotalLab Quant (TotalLab Limited). 
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Apoptosis 
For detection of apoptosis, cells were either transfected with siRNA as described above or incubated 
for 16-24h in the presence or absence of the inhibitors and the Cell Death detection ELISA method 
(Roche Diagnostics) was used for detection of apoptosis. Alternatively, apoptosis was also measured 
by propidium iodide staining followed by flow cytometry as previously described (21). Caspase 3/7 
activity was measured by using the Caspase-Glo 3/7 Assay (Promega). 
 
Statistical analysis  
All tests were performed using GraphPad PRISM 4.03 software. Descriptive statistics including mean 
and standard error of the mean, one-way ANOVA's and Student’s two-tailed t-tests were used. p 
values<0.05 were considered significant. 
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Results 
 
Identification of protein and lipid kinases involved in medulloblastoma cell proliferation and 
cisplatin sensitivity 
To identify genes essential for medulloblastoma cell proliferation and involved in cellular responses to 
cisplatin treatment, we designed a robust, cell-based high-throughput kinome-wide RNA interference 
screen. We systematically inactivated all human protein and lipid kinase genes by RNAi and scored 
them for inhibition of cell proliferation, in the presence and absence of low dose cisplatin. DAOY 
medulloblastoma cells were transfected with a 96-well plate arrayed library of siRNA duplexes 
targeting each of the 719 human kinase genes. We chose the DAOY cell line for the screen, as well as 
UW-228 and PFSK cell lines for validation experiments, since our previous published work has 
characterised these cell lines in terms of response to cisplatin and activation of various survival 
pathways (11, 19, 22-24). The characteristics of the cell lines under study are described in the 
Supplementary Table S1. We first assessed viability effects induced by siRNAs, in the absence of 
cisplatin treatment. In the screen, kinases involved in proliferations were defined as kinases whose 
down-regulation led to a >25% decrease in cell proliferation compared to the scrambled controls, with 
at least two individual siRNA sequences. In large-scale screens, confirmation of an observed 
phenotype with redundant silencing reagent offers the most straightforward way of demonstrating 
RNAi target specificity, allowing exclusion of possible off-target effects (25). Overall, 31 kinases were 
identified as kinases involved in proliferation (Fig. 1A), with siRNAs targeting MPP2 (membrane 
protein, palmitoylated 2 (MAGUK p55 subfamily member 2) and PLK1 (polo-like kinase 1) having the 
most prominent effect (Fig. 1A). One of the kinases involved in proliferation identified, the proto-
oncogene PIK3CA, encoding for the PI3K class IA catalytic subunit p110α, had been characterized in 
our previous studies as an important mediator of medulloblastoma cell survival, regulating 
proliferation, response to polypeptide growth factor stimulation, apoptosis and cell migration (11). 
To identify kinases involved in proliferation that further have a role in cellular responses to 
cisplatin treatment, we performed a secondary sensitized screen in the presence of low doses of 
cisplatin. The dose of cisplatin chosen for the screen was determined to induce 20% killing in DAOY 
cells. We first analysed the sensitivity ratios between vehicle- and cisplatin-treated cells. Fig. 1B 
shows all kinases, that when down-regulated led to a sensitization to cisplatin treatment, with at least 
two unique siRNA sequences. Cisplatin is a platinum-based chemotherapeutic drug which covalently 
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binds to purine DNA bases leading to DNA-platinum adducts formation and cellular apoptosis (26). It is 
one of first and still most commonly used chemotherapeutic drugs, and much is now understood as to 
how tumors exhibit or acquire resistant to cisplatin treatment (26). Generally, 24 genes were identified 
as enhancing cell sensitivity to the drug treatment (Fig. 1B); amongst the top hits of our sensitized 
screen were kinases known to be involved in cellular response to cisplatin treatment, such as the 
checkpoint kinases ATR, ATM and CHK1, from the double strand DNA repair mechanisms (Fig. 1B). 
Of the remaining 21 hits, 6 had also shown to have a positive regulatory effect on cell proliferation 
(Fig. 1A) and were re-examined (Fig. 4A). Z-score analysis revealed a normal distribution of the siRNA 
hits (Fig. 1C). 
 
PLK1 silencing or inhibition inhibits medulloblastoma cell proliferation 
The protein kinase PLK1, which was identified in the survival screen (Fig. 1A), plays an essential role 
during mitosis and maintenance of genomic stability (27). Cancer cells, but not normal cells, have 
been shown to be susceptible to PLK1 depletion (28), particularly p53-defective cell lines (29). The 
siRNAs targeting PLK1 were re-assayed in DAOY, PFSK and UW-228 medulloblastoma cell lines (Fig. 
2A). Silencing of PLK1 strongly impaired DAOY and PFSK cell proliferation, whereas no effect was 
observed in UW-228 cells (Fig. 2A). The siRNAs to PLK1 were shown to reduce target mRNA and 
protein levels by more than 60% (Fig. 2B). Greater than twofold increase in apoptosis was observed 
upon down-regulation of PLK1 in DAOY cell line (Fig. 2C). Recent studies have demonstrated that the 
small molecule inhibitor BI2536, a potent and selective inhibitor of PLK1, suppressed growth of a 
panel of human cancers in vivo (30, 31). We then investigated the effects of BI 2536 treatment in 
medulloblastoma cell proliferation in the cell lines under study. A strong inhibitory effect was observed 
in the p53-mutant cell line DAOY (IC50 2.5-5 nM), whereas growth of PFSK and UW-228 cells was 
only partially reduced (Fig. 2D). These results, in line with the observations upon depletion of PLK1 by 
siRNA, demonstrate that PLK1 potently controls cell proliferation in medulloblastoma cells, 
underscoring the role of PLK1 in oncogenic signalling. 
  
PIK3CG and LYK5 silencing inhibits cell proliferation and increases sensitivity to cisplatin 
treatment 
Two genes identified in the sensitised siRNA screen (Fig. 1) were further validated with two siRNA and 
one shRNA sequences in three medulloblastoma cell lines, DAOY, PFSK and UW-228 cells: the 
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phosphoinositide-3-kinase, catalytic, gamma polypeptide (PIK3CG; gene ID 5294) and the protein 
kinase LYK5 (LYK5; gene ID 92335) (Fig. 3, Fig. 4A and Fig. S1A). The siRNAs targeting PIK3CG and 
LYK5 were shown to reduce target mRNA levels by more than 85% (Fig. 3A and Supplementary Fig. 
S3), which was accompanied by a decrease in protein levels (Fig. 3C). Silencing of PIK3CG strongly 
impaired DAOY and PFSK cell proliferation, whereas a lesser effect was observed in UW-228 cells 
(Fig. 3B). UW-228 cells displayed low p110γ expression, possibly explaining the fact that they are less 
sensitive to PIK3CG silencing (Fig. 3B and Fig. 6D). Silencing of LYK5 also strongly impaired DAOY, 
PFSK and UW-228 cell proliferation, although some differences were observed between the cell lines 
(Fig. 3B). Down-regulation of LYK5 and PIK3CG induced apoptosis in the three medulloblastoma cell 
lines, suggesting that cell death contributes to the effects of the siRNAs on cell survival (Fig. 3D).  
Analysis of the phosphorylation status of downstream molecules following silencing of PIK3CG 
revealed an inhibition of basal phosphorylation of the S6 ribosomal protein at the Ser 235/236 and at 
Ser 240/244 sites, as well as 4E-BP1 phosphorylation (Fig. 3C). Silencing of LYK5 induced a marked 
decrease in LKB1 protein expression, while the levels of AMPKα were not affected (Fig. 3C). This 
downregulation of LKB1 expression upon LYK5 silencing was observed in all three medulloblastoma 
cell lines under study (Fig. 3C and data not shown). Under these experimental conditions, we did not 
detect any phosphorylation of AMPKα at Thr172 (data not shown). Silencing of LYK5 also resulted in 
an inhibition of basal phosphorylation of 4E-BP1 (Fig. 3C). Together these results suggest that 
PIK3CG and LYK5 are involved in the activation of the mTOR/S6K pathway in medulloblastoma cells. 
To confirm the validity of the results from the sensitised siRNA screen, 6 genes that had also 
been shown to have a positive regulatory effect on cell proliferation (Fig. 1A) were re-examined in 
proliferation assays in DAOY cells (Fig. 4A) and UW-228 cells (Fig. 4B). Down-regulation of target 
gene expression was validated by quantitative PCR (TaqMan) in the two medulloblastoma cell lines 
(Supplementary Fig. S3).  These experiments showed that silencing of ATR, LYK5, PIK3CG and 
MPP2 enhanced the effects of cisplatin in both cell lines (Fig. 4A and 4B). Further confirmation was 
provided by establishing dose-response curves upon siRNA mediated silencing of PIK3CG (Fig. 4B). 
siRNA-mediated silencing of PIK3CG lowered the EC50 of cisplatin from 1.9 μM to 0.6 μM (a 3-fold 
reduction). shRNA-mediated silencing of LYK5, PIK3CG and MPP2 also significantly lowered the EC50 
from 5μM to 0.5-1μM (a 5 to 10-fold reduction), increasing sensitivity to cisplatin treatment 
(Supplementary Fig. S1B). To test whether this effect is due to an increase in the activity of the 
apoptotic machinery, we analysed cisplatin-induced apoptosis in cells depleted of PIK3CG and LYK5 
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by treating the cells with cisplatin 24h after transfection for an additional 24h. Analysis of PARP 
cleavage by Western blot revealed a dose-dependent increase in apoptosis upon cisplatin treatment, 
which was more pronounced in cells where PIK3CG was down-regulated (Fig. 4C). Furthermore, 
relative quantification of histone-complexed cytoplasmatic DNA fragments confirmed that siRNAs for 
PIK3CG and LYK5 siRNAs sensitised DAOY cells to cisplatin induced apoptosis (data not shown). 
 
Effects of a PI3K p110γ small molecule inhibitor on medulloblastoma cell proliferation, cell 
death and pathway activation 
The class IB phosphatidylinositol 3-kinase has been focus of intensive research and is regarded as a 
promising therapeutic target, particularly in inflammatory diseases (32). Consequently, a number of 
small molecule inhibitors have been developed and their potential therapeutic applications extensively 
studied in preclinical models (32). Using a novel PI3K p110γ small molecule inhibitor, AS252424, we 
investigated whether the RNAi-mediated effects observed on cell proliferation and response to 
cisplatin could be reproduced by means of pharmacological targeting of this kinase. After treatment for 
72h, AS252424 was shown to decrease the proliferation of 5 medulloblastoma cell lines, including 
DAOY and PFSK cells in a dose-dependent manner, with IC50 values in the range of 1-15 μM (Fig. 
5A).  Cell lines with low p110γ expression, such as UW-228 and D425, were less sensitive to 
AS252424 (Fig. 5A and Fig. 6D). However, there was no significant correlation between the IC50 
values and the expression of p110γ in the 6 medulloblastoma cell lines under study (Pearson 
correlation coefficient R=-0.5721, P=0.2354). These observations suggest that other factors modulate 
the sensitivity of medulloblastoma cells to the pharmacological inhibitor of p110γ. Analysis of the 
phosphorylation status of downstream molecules following treatment with AS252424 revealed 
concentration-dependent inhibition of basal phosphorylation of Akt, at the Thr 308 and Ser 437 sites, 
and S6 ribosomal protein at the Ser 240/244 (Fig. 5B). Furthermore, 24h-treatment with AS252424 
enhanced cisplatin-induced apoptosis in medulloblastoma cells (Fig. 5C and data not shown). Our 
previous studies have shown that treatment with chemotherapeutic agents such as doxorubicin leads 
to activation of the PI3K/Akt pathway in medulloblastoma cells (11). It has been shown in several 
human cancer cells that activation of the PI3K/Akt pathway renders cells resistant to commonly used 
chemotherapeutic agents, including cisplatin and other platinum-based drugs (33, 34). In line with 
what was observed upon RNAi-mediated down-regulation of p110γ, AS252424 increased the levels of 
apoptosis induced by cisplatin treatment, sensitizing cells to cisplatin-induced cell death (Fig. 5C). 
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Furthermore, treatment of DAOY cells with the p110γ inhibitor AS 252424 decreased cisplatin-induced 
phosphorylation of Akt and S6 protein (Fig. 5D). These results unveil a novel role for PI3K p110γ in 
human medulloblastoma, as a positive regulator of cell proliferation and underline the importance of 
PI3K p110γ in modulating cellular responses upon cisplatin treatment.  
 
Expression of PIK3CG and LYK5 in human medulloblastomas 
We next re-analysed expression profiles obtained from DNA microarray analysis in medulloblastoma 
(17). From the genes identified in the RNAi screen in medulloblastoma (Fig. 1), PLK1, PIK4CA and 
WNK4 showed no significant change in medulloblastoma, compared to normal cerebellum. In contrast, 
ATR and LYK5 displayed higher expression in medulloblastoma (Figure S2A and S2D), while MPP2 
expression was lower (Figure S2C). We next performed additional experiments to verify that PIK3CG 
and LYK5 are differentially expressed in human medulloblastoma primary tumors. We initially 
analyzed mRNA expression by quantitative RT-PCR in a set of representative medulloblastoma 
surgical specimens. LYK5 was found to be commonly over-expressed in medulloblastomas (20/23, 
87%) whereas up-regulation of PIK3CG was restricted to a subset of tumors (9/17, 53%), compared to 
normal cerebellum (Fig. 6A and B). Protein expression levels were further analyzed by Western blot 
and expression of PI3K p110γ was detected in 13/19 of the samples under study (Fig. 6C, 68%). In 
addition, PI3K p110γ and LYK5 expression was detected in 5/7 (71%) of the medulloblastoma cell 
lines under study (Fig. 6D). In the case of LYK5 there was no significant correlation between mRNA 
and protein expression levels in the cell lines (Pearson correlation coefficient R=0.6587, P=0.1548) 
(Fig. 6D and Fig. S2F). In the case of p110γ the mRNA and protein levels did not significantly correlate 
(Pearson correlation coefficient R= -0.2183, P=0.7817 ) (Fig. 6A, 6C, 6D and Fig. S2E). 
We next reanalyzed a set of Affymetrix Human Genome U133 Plus 2.0 microarray data 
comprising expression profiles on a series of 47 medulloblastoma patient samples and 9 normal 
cerebellum samples. This analysis revealed a significant up-regulation of the gene encoding for LYK5 
in medulloblastomas compared to normal cerebellum (Supplementary Fig. S2A). Interestingly, LYK5 
was found to be expressed at significantly higher levels in medulloblastomas presenting typical 17p 
breakpoints when compared to the group of medulloblastomas without 17p breakpoints 
(Supplementary Fig. S2B). The analysis of the tumor samples for PIK3CG expression showed variable 
expression of the gene. A fraction of medulloblastoma tumors also displayed PIK3CG over-expression 
(data not shown).  
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Discussion 
 
The present report represents one of the first kinome-wide RNAi screens in human brain tumor cell 
lines and in medulloblastoma. Ideally, such loss-of-function screens should lead to the identification of 
novel targets for the development of therapeutic strategies for these malignancies, which are 
associated with a poor outcome in patients (16). Our studies have identified two distinct panels of 
kinases that contribute to cell proliferation and to the sensitivity of medulloblastoma cells to the 
commonly used chemotherapeutic agent cisplatin.  
 As a validation of the survival screen, we performed additional experiments to assess the 
contribution of PLK1 to medulloblastoma cell proliferation. A pharmacological inhibitor of PLK1 (BI 
2536) (31) reduced cell proliferation in DAOY cells, but was less potent in other medulloblastoma cell 
lines. In addition, siRNA-mediated downregulation of PLK1 had more pronounced effects than the 
inhibitor in some cell lines, such as PFSK. These contrasting results could potentially be explained by 
differences in PLK1 expression between the cell lines, and in p53 status, since it was previously 
shown that PLK1 depletion has more prominent effects in a mutant p53 background (28), which is the 
case for DAOY. It is also conceivable that there may be a kinase-independent function of PLK1 in cell 
proliferation in medulloblastoma. 
When combining the results of the two RNAi screens, a set of 6 genes comprising ATR, LYK5, 
MPP2, PIK3CG, PIK4CA and WNK4 were identified as contributing to both cell proliferation and 
resistance to cisplatin treatment in the DAOY medulloblastoma cell line. It is interesting to note here 
that several protein and lipid kinases were previously identified in comparable sensitised RNAi screens 
in different human cancer cell lines, including Akt, ATM, ATR, BUB1, phosphatidylinostiol 4-kinase and 
phosphatidylinositol 3-kinase (13, 14). The identities of the PI-kinase isoforms were however different 
between our study and previous reports (13, 14). A MAGUK family member, namely MPP7 was also 
identified in an RNAi screen in lung cancer cells investigating paclitaxel resistance (15). 
We focused our attention on two genes involved in medulloblastoma proliferation and 
chemoresistance, namely LYK5 and  PIK3CG. This was based on an analysis of the expression of the 
targets identified in the RNAi screens, which revealed an up-regulation of the expression of these two 
kinases in subsets of primary medulloblastoma tumor samples and cell lines.  
LYK5 is involved in the regulation, assembly and localization of LKB1 and the LKB1-
dependent AMPK pathway (35). In medulloblastoma cells, silencing of LYK5 induced a pronounced 
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down-regulation of LKB1 expression, indicating that LYK5 may be required for LKB1 stability. The 
AMPK pathway has been studied as a potential target for the development of anti-cancer drugs in 
various human malignancies (36). Activation of AMPK suppresses the mTOR pathway directly or 
indirectly via TSC2. The mTOR pathway has been recognized as an important regulator of the 
sensitivity of human cancer cells to chemotherapeutic agents (13, 37). Indeed, in a previous study, 
rapamycin exhibited additive cytotoxicity with cisplatin in DAOY cells (10). Although LKB1 is generally 
thought to function as a tumor suppressor, recent work has also documented its role in the 
phosphorylation of pro-apototic proteins by Akt (38). Together with our data, this may indicate that 
LYK5/LKB1 may function as a positive regulator of the mTOR/4E-BP1 pathway in medulloblastoma. 
The present study represents the first reports on a role for p110γ as a drug target in brain 
tumors. Genetic targeting of PIK3CG in mice has underlined a central role of this PI3K isoform in 
inflammation and allergy, as it modulates chemotaxis of leukocytes and degranulation in mast cells 
(39). In colorectal cancers, PIK3CG was initially proposed to function as a tumor suppressor gene 
(40), a finding disputed by a subsequent study (41). An oncogenic potential was then described for 
p110γ, similarly to other class IA PI3K isoforms (42, 43). A recent study described a critical role for 
p110γ in pancreatic cancer, and hypothesized that PI3K/p110gamma over-expression is a key event in 
the disease progression (44). 
The availability of isoform-specific p110γ inhibitors allowed the design of validation 
experiments to assess the feasibility of targeting this PI3K isoform in medulloblastoma cell lines. 
Indeed, our results showed for the first time that a pharmacological p110γ inhibitor impaired the 
proliferation of medulloblastoma cells and the activation of the mTOR/S6K pathway. The 
Akt/mTOR/S6K pathway was previously shown to be constitutively activated in primary 
medulloblastoma and cell lines (11). Our data suggest that p110γ and LYK5 contribute to this 
activation, in view of:  (i) the over-expression of p110γ and LYK5 in medulloblastoma; and (ii) the 
negative impact of targeting these kinases on the basal activation of the pathway in medulloblastoma 
cell lines. 
In addition, the pharmacological p110γ inhibitor sensitised medulloblastoma cells to cisplatin-
induced apoptosis. These effects could be explained by the ability of the p110γ inhibitor to impair basal 
and cisplatin-induced activation of Akt in medulloblastoma cells. Therefore, more work is warranted to 
validate p110γ as a novel drug target in medulloblastoma. Our previous findings described a role for 
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the class IA PI3K p110α isoform in medulloblastoma proliferation and resistance to doxorubicin (11). 
However, p110α was not identified in the sensitised RNAi screen with cisplatin, suggesting that 
different class I PI3K isoforms may contribute to resistance to cisplatin or doxorubicin. Thus, targeting 
PI3K signalling may represent an attractive novel approach to develop novel therapies for 
medulloblastoma. Indeed, there now exist different pharmacological inhibitors of PI3K which have 
entered clinical trials for adult cancer and could, in the future, be also considered for medulloblastoma 
(12, 45-47). 
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Figure legends 
 
Figure 1. Human kinase siRNA high-throughput screen: kinases involved in proliferation and kinases 
involved in resistance to cisplatin treatment. A, The figure represents kinases, down-regulation of 
which led to a >25% decrease in cell proliferation compared to a negative control, with at least two 
unique siRNA sequences. For each siRNA sequence, averages of 3 independent experiments are 
shown using a color-coding format. B, 24h following transfection, cells were treated with 0.5 μM 
cisplatin for 48hr, before cell proliferation was measured using MTS assay. The figure represents 
kinases, down-regulation of which led to a sensitization to cisplatin treatment, with at least two unique 
siRNA sequences. For each siRNA sequence 3 independent experiments were performed, ratio 
between vehicle- and cisplatin-treated cells were calculated and values >1.5 were considered 
significant. Sensitivity ratios are shown using a colour-coding format. C, Scatter plot of averaged Z 
scores from cisplatin sensitivity screen.  
 
Figure 2. Effects of targeting polo-like kinase 1 in medulloblastoma cell lines. A, RNAi-mediated down-
regulation of PLK1 decreased proliferation of DAOY (black bars), PFSK (grey bars) and UW-228 
(white bars) cells. In DAOY cells strong inhibition of cell proliferation is observed, whereas depletion of 
PLK1 had no effect in UW-228 cell. B, RT-PCR showing both positive siRNA sequences inducing 
similar levels of downregulation of PLK1 mRNA 48h following transfection (top panel). Western blot 
analysis confirming PLK1 down-regulation by the siRNA in the 3 cell lines (mid panel). TaqMan-based 
qRT–PCR confirmed downregulation of PLK1 mRNA in the 3 cell lines. DAOY (black bars), PFSK 
(grey bars) and UW-228 (white bars) (bottom panel). C, Down-regulation of PLK1 induces apoptosis in 
DAOY cells. D, PLK1 small molecule pharmacological inhibitor, BI 2536, strongly impaired DAOY cell 
proliferation, whereas growth of PFSK and UW-228 was only partly inhibited (DAOY: black bars; 
PFSK: grey bars; UW-228: white bars). * P <0.05, compared with control.  
 
Figure 3. PIK3CG and LYK5: roles in proliferation, apoptosis and chemoresistance. A, RNAi-mediated 
down-regulation of PIK3CG and LYK5 mRNA expression in DAOY cells. B, RNAi-mediated down-
regulation of PIK3CG and LYK5 decreased proliferation of DAOY (black bars), PFSK (grey bars) and 
UW-228 (white bars) cells. C, In DAOY cells, RNAi-mediated targeting of PIK3CG led to 
downregulation of PI3K p110γ protein expression and inhibited phosphorylation of S6 and 4E-BP1 
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downstream signalling proteins. RNAi-mediated targeting of LYK5 led to downregulation of LYK5 
protein expression, LKB1 downregulation and inhibited phosphorylation of 4EBP1 protein. D, RNAi-
mediated down-regulation of PIK3CG and LYK5 increased apoptosis in DAOY (black bars), PFSK 
(grey bars) and UW-228 (white bars) cells. * P <0.05, compared with control. 
 
 
Figure 4. Kinases involved in cell proliferation and chemoresistance. A, The graph shows siRNA-
mediated effects in DAOY cell proliferation in the presence (0.5 μM; white bars) and absence (grey 
bars) of cisplatin for those kinases that scored positive in both screens. B, The graph shows siRNA-
mediated effects on UW-228 cell proliferation in the presence of cisplatin (2.0 μM) for those kinases 
that scored positive in both screens. The ratio of cell proliferation of cells treated with cisplatin to 
vehicle-treated cells is presented. C, RNAi-mediated targeting of PIK3CG led to sensitization of DAOY 
cells to cisplatin treatment (siRNA control: black circles; siRNA PIK3CG: white circles). D,  RNAi-
mediated targeting of PIK3CG enhanced cisplatin-induced apoptosis, as measured by Western blot 
analysis of PARP cleavage. * P<0.05, cisplatin-treated sample compared with control. 
 
Figure 5. Effects of treatment with a novel small kinase inhibitor of PI3K p110γ on medulloblastoma 
cells. A-C, Pharmacological inhibition of the PI3K p110γ isoform, the protein encoded by PIK3CG, led 
to inhibition of cell proliferation (black diamonds: DAOY; black squares: PFSK; black triangles: UW-
228; white squares: D341; black circles: D458; white circles D425) (A), inhibition of basal 
phosphorylation of Akt in DAOY cells (B), increased cisplatin-induced apoptosis (black bars: 0μM 
AS252424; grey bars: 1μM AS252424) in PFSK cells (C) and impaired cisplatin-induced 
phosphorylation of Akt in DAOY cells (D). 
 
Figure 6. Relative expression levels of the kinases LYK5 and p110γ in primary medulloblastoma tumor 
samples. A-B, Gene expression ratios (log scale) measured in tumors by TaqMan-based qRT–PCR. 
The relative gene expression level is presented as fold change of tumor versus normal cerebellum. 
Error bars are too small to be seen. Samples from series 1 were from the Necker Hospital Tumor (17). 
Samples from series 2 were from the SPOG (Table S2). C, Protein expression of p110γ was analyzed 
in an additional, independent set of medulloblastoma tumor surgical specimens (N=19, Table S2). D, 
Protein expression of LYK5 and p110γ was analyzed in human medulloblastoma cell lines (N=7). 
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Whole cell lysate was extracted and total protein was analyzed for p110γ and β-Actin by Western Blot. 
Tumors and cells lines commonly over-express LYK5 and p110γ. In Figure 6A Samples 14-17 
correspond to the tumor samples nr. 4, 12, 15 and 18 in Figure 6C. Samples 14-23 in Figure 6B 
correspond to the tumor samples nr. 4-9, 11, 12, 15 and 18 in Figure 6C. 
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